Inhaled ENaC antisense oligonucleotide ameliorates cystic fibrosis-like lung disease in mice.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Cystic Fibrosis

• Publication date

  2017-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jcf.2017.05.003PMID 28539224
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Future trends in cystic fibrosis demography in 34 European countries

  2015cited by this paper
• Targeting ion channels in cystic fibrosis.

  2015cited by this paper
• Local and systemic tolerability of a 2′O-methoxyethyl antisense oligonucleotide targeting interleukin-4 receptor-α delivery by inhalation in mouse and monkey

  2014cited by this paper
• CFTR: cystic fibrosis and beyond

  2014cited by this paper
• Acute Hyperkalemia Associated with Inhalation of a Potent ENaC Antagonist: Phase 1 Trial of GS-9411

  2014cited by this paper
• Pharmacological Characterization of a Novel ENaCα siRNA (GSK2225745) With Potential for the Treatment of Cystic Fibrosis

  2013cited by this paper
• Molecular basis for pH-dependent mucosal dehydration in cystic fibrosis airways

  2013cited by this paper
• Does epithelial sodium channel hyperactivity contribute to cystic fibrosis lung disease?

  2013cited by this paper
• The CFTR and ENaC debate: how important is ENaC in CF lung disease?

  2012cited by this paper
• Deletion of the ubiquitin ligase Nedd4L in lung epithelia causes cystic fibrosis-like disease

  2011cited by this paper
• Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation

  2011cited by this paper
• Regulation of endogenous ENaC functional expression by CFTR and ΔF508-CFTR in airway epithelial cells.

  2011cited by this paper
• Respiratory distress and perinatal lethality in Nedd4-2-deficient mice

  2011cited by this paper
• RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform.

  2010cited by this paper
• Randomized, Double-Blind, Placebo Controlled First in Human Study of Inhaled AIR645, an IL-4Rα Oligonucleotide, in Healthy Volunteers.

  2009cited by this paper
• Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues.

  2009cited by this paper
• Specific inhibition of epithelial Na+ channels by antisense oligonucleotides for the treatment of Na+ hyperabsorption in cystic fibrosis

  2009cited by this paper
• Preventive but not late amiloride therapy reduces morbidity and mortality of lung disease in betaENaC-overexpressing mice.

  2008cited by this paper
• Mechanisms of ENaC regulation and clinical implications.

  2008cited by this paper
• Identification of the Cystic Fibrosis Gene : Chromosome Walking and Jumping Author ( s ) :

  2008cited by this paper
• Inhaled CD86 Antisense Oligonucleotide Suppresses Pulmonary Inflammation and Airway Hyper-Responsiveness in Allergic Mice

  2007cited by this paper
• Anti-inflammatory activity of inhaled IL-4 receptor-alpha antisense oligonucleotide in mice.

  2007cited by this paper
• Anti-Inflammatory Activity of Inhaled IL-4 Receptor-α Antisense Oligonucleotide in Mice

  2007cited by this paper
• Mucus clearance and lung function in cystic fibrosis with hypertonic saline.

  2006cited by this paper
• Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice

  2004cited by this paper
• A novel mouse Nedd4 protein suppresses the activity of the epithelial Na+ channel

  2001cited by this paper
• Pharmacokinetic and Toxicity Profile of a Phosphorothioate Oligonucleotide Following Inhalation Delivery to Lung in Mice

  2000cited by this paper
• On the Molecular Basis of Ion Permeation in the Epithelial Na+ Channel

  1999cited by this paper
• Antisense oligonucleotides against the α-subunit of ENaC decrease lung epithelial cation-channel activity.

  1999cited by this paper
• Epithelial sodium channels: function, structure, and regulation.

  1997cited by this paper
• 2′-O-(2-Methoxy)ethyl-modified Anti-intercellular Adhesion Molecule 1 (ICAM-1) Oligonucleotides Selectively Increase the ICAM-1 mRNA Level and Inhibit Formation of the ICAM-1 Translation Initiation Complex in Human Umbilical Vein Endothelial Cells*

  1997cited by this paper
• Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography.

  1997cited by this paper
• Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid.

  1996cited by this paper
• CFTR as a cAMP-dependent regulator of sodium channels

  1995cited by this paper
• Amiloride-sensitive epithelial Na+ channel is made of three homologous subunits

  1994cited by this paper
• Defective Epithelial Chloride Transport in a Gene-Targeted Mouse Model of Cystic Fibrosis

  1992cited by this paper
• Demonstration that CFTR is a chloride channel by alteration of its anion selectivity.

  1991cited by this paper
• A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis.

  1990cited by this paper
• Identification of the cystic fibrosis gene: genetic analysis.

  1989cited by this paper
• Identification of the cystic fibrosis gene: chromosome walking and jumping.

  1989cited by this paper

• Restoring chloride efflux in cystic fibrosis with TMEM16a antisense oligonucleotides

  2025cites this paper
• Inhaled non-viral delivery systems for RNA therapeutics

  2025cites this paper
• An antisense oligonucleotide targeting the heat‐shock protein HSPB5 as an innovative therapeutic approach in pulmonary fibrosis

  2025cites this paper
• Energy deficiency selects crowded live epithelial cells for extrusion

  2025cites this paper
• Randomised, phase 1/2a trial of ION-827359, an antisense oligonucleotide inhibitor of ENaC

  2024cites this paper
• Tissue pharmacokinetics of antisense oligonucleotides

  2024cites this paper
• Functional Consequences of CFTR Interactions in Cystic Fibrosis

  2024cites this paper
• Mycobacterium abscessus pulmonary infection and associated respiratory function in cystic fibrosis-like βENaC mice

  2024cites this paper
• Systematic deletion of symmetrical CFTR exons reveals new therapeutic targets for exon skipping antisense oligonucleotides

  2024cites this paper
• Current and future therapeutic approaches of CFTR and airway dysbiosis in an era of personalized medicine

  2024cites this paper
• Gene, RNA, and ASO-based therapeutic approaches in Cystic Fibrosis.

  2023cites this paper
• Inhalable Bottlebrush Polymer Bioconjugates as Vectors for Efficient Pulmonary Delivery of Oligonucleotides

  2023cites this paper
• Inhaled RNA drugs to treat lung diseases: Disease-related cells and nano-bio interactions.

  2023cites this paper
• Role of epithelial sodium channel-related inflammation in human diseases

  2023cites this paper
• The Epithelial Sodium Channel—An Underestimated Drug Target

  2023cites this paper
• Voltage-dependent volume regulation controls epithelial cell extrusion and morphology

  2023cites this paper
• Antisense oligonucleotides to therapeutically target SARS-CoV-2 infection

  2023cites this paper
• Simultaneous inhibition of endocytic recycling and lysosomal fusion sensitizes cells and tissues to oligonucleotide therapeutics

  2023cites this paper
• Delivery Characterization of SPL84 Inhaled Antisense Oligonucleotide Drug for 3849 + 10 kb C- > T Cystic Fibrosis Patients

  2023cites this paper
• Small Drugs, Huge Impact: The Extraordinary Impact of Antisense Oligonucleotides in Research and Drug Development

  2022cites this paper
• Oligonucleotide-based therapies for cystic fibrosis.

  2022cites this paper
• Intratracheally administered LNA gapmer antisense oligonucleotides induce robust gene silencing in mouse lung fibroblasts

  2022cites this paper
• Advances in the design of new types of inhaled medicines.

  2022cites this paper
• Sustained inhibition of ENaC in CF: Potential RNA-based therapies for mutation-agnostic treatment.

  2022cites this paper
• Downregulation of epithelial sodium channel (ENaC) activity in cystic fibrosis cells by epigenetic targeting

  2022cites this paper
• Open reading frame correction using splice-switching antisense oligonucleotides for the treatment of cystic fibrosis

  2022cites this paper
• Fighting the Fiber: Targeting Collagen in Lung Fibrosis.

  2021cites this paper
• Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849 + 10 kb C-to-T splicing mutation

  2021cites this paper
• Antisense technology: an overview and prospectus

  2021cites this paper
• Modulation of Ion Transport to Restore Airway Hydration in Cystic Fibrosis

  2021cites this paper
• DNA Methylation Patterns Correlate with the Expression of SCNN1A, SCNN1B, and SCNN1G (Epithelial Sodium Channel, ENaC) Genes

  2021cites this paper
• Charge‐Conversion Strategies for Nucleic Acid Delivery

  2021cites this paper
• Cystic Fibrosis Cellular Treatments

  2021cites this paper
• Overcoming the challenges of tissue delivery for oligonucleotide therapeutics.

  2021cites this paper
• Large Clostridial Toxins: Mechanisms and Roles in Disease

  2021influential citation
• Function and Regulation of the Epithelial Na+ Channel ENaC.

  2021cites this paper
• Enhanced delivery of peptide-morpholino oligonucleotides with a small molecule to correct splicing defects in the lung

  2021cites this paper
• New Therapies to Correct the Cystic Fibrosis Basic Defect

  2021cites this paper
• Gene-specific nonsense-mediated mRNA decay targeting for cystic fibrosis therapy

  2021cites this paper
• Open reading frame correction using antisense oligonucleotides for the treatment of cystic fibrosis caused by CFTR-W1282X

  2021cites this paper
• Exon-skipping antisense oligonucleotides for cystic fibrosis therapy

  2021cites this paper
• HOXD9-induced SCNN1A upregulation promotes pancreatic cancer cell proliferation, migration and predicts prognosis by regulating epithelial-mesenchymal transformation

  2021cites this paper
• Small-molecule drugs for cystic fibrosis: Where are we now?

  2021cites this paper
• Antisense oligonucleotide: A promising therapeutic option to beat COVID‐19

  2021cites this paper
• Inhibition of SARS-CoV-2 by Targeting Conserved Viral RNA Structures and Sequences

  2021cites this paper
• Exploiting the diphtheria toxin internalization receptor enhances delivery of proteins to lysosomes for enzyme replacement therapy

  2020cites this paper
• Azithromycin inhibits constitutive airway epithelial sodium channel activation in vitro and modulates downstream pathogenesis in vivo.

  2020cites this paper
• New approaches to genetic therapies for cystic fibrosis.

  2020cites this paper
• Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting

  2020cites this paper
• Perspectives on Lung Dose and Inhaled Biomolecules

  2020cites this paper
• Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting

  2020cites this paper
• ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies

  2020cites this paper
• Novel Anti-Inflammatory Approaches for Cystic Fibrosis Lung Disease: Identification of Molecular Targets and Design of Innovative Therapies

  2020cites this paper
• Cystic Fibrosis: Overview of the Current Development Trends and Innovative Therapeutic Strategies

  2020cites this paper
• Gene Therapy for Cystic Fibrosis: Progress and Challenges of Genome Editing

  2020cites this paper
• Antisense oligonucleotide-mediated correction of CFTR splicing improves chloride secretion in cystic fibrosis patient-derived bronchial epithelial cells

  2020cites this paper
• STATE OF THE ART Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications

  2020cites this paper
• Chitosan Nanocomplexes for the Delivery of ENaC Antisense Oligonucleotides to Airway Epithelial Cells

  2020cites this paper
• Antisense Oligonucleotides Targeting Jagged 1 Reduce House Dust Mite-Induced Goblet Cell Metaplasia in the Adult Murine Lung.

  2020cites this paper
• Nucleic Acid-Based Technologies Targeting Coronaviruses

  2020cites this paper
• Novel therapeutic approaches for the management of cystic fibrosis

  2020cites this paper
• Symposium Summaries

  2019cites this paper
• Nonsense Mediated RNA Decay Pathway Inhibition Restores Expression and Function of W1282X CFTR.

  2019cites this paper
• Antisense oligonucleotide targeting of mRNAs encoding ENaC subunits α, β, and γ improves cystic fibrosis-like disease in mice.

  2019cites this paper
• Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications.

  2019cites this paper
• Emerging Therapeutic Approaches for Cystic Fibrosis. From Gene Editing to Personalized Medicine

  2019cites this paper
• Steric Inhibition of 5′ UTR Regulatory Elements Results in Upregulation of Human CFTR

  2019cites this paper
• Recent advances in developing therapeutics for cystic fibrosis.

  2018cites this paper
• Ion Channel Modulators in Cystic Fibrosis

  2018cites this paper
• Inhibition of the extrinsic or intrinsic coagulation pathway during pneumonia-derived sepsis.

  2018cites this paper
• The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis lung disease

  2018cites this paper
• Emerging Concepts and Therapies for Mucoobstructive Lung Disease

  2018cites this paper
• Nucleic Acid-Based Therapeutics for Pulmonary Diseases

  2018cites this paper
• The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis

  2018cites this paper
• Emerging microRNA Therapeutic Approaches for Cystic Fibrosis

  2018cites this paper
• Oligonucleotide Therapies for the Lung: Ready to Return to the Clinic?

  2017cites this paper
• Nucleic Acid Therapies for Cystic Fibrosis

  2017cites this paper